Morristown, NJ—OmniActive Health Technologies’ CurcuWIN was shown in a new study to benefit athletes by preserving muscle performance and reducing soreness following exercise, according to a press release.
The eight-week human clinical trial, published in Nutrients, was double-blind, randomized, placebo-controlled, and parallel designed. It tested the effects of 250mg of the enhanced curcumin product CurcuWIN, 1000mg of CurcuWIN, or placebo on 63 physically active men and women.
After the supplementation period, subjects completed a downhill running protocol designed to induce muscle damage. Muscle function and soreness was assessed prior to the run and at 1 hour, 24 hours, 48 hours, and 72 hours post-run. Isokinetic peak extension torque didn’t change in the 1000mg dose, but significant reductions occurred in the placebo and 250mg groups through the first 24 hours of recovery. The 1000mg group saw reductions in soreness, but the reductions didn’t reach statistical significance.
Dr. Ralf Jager, co-founder and managing member of Increnovo LLC and lead author of the publication, said in the press release: “Intense exercise causes muscle damage, inflammation and oxidative stress, resulting in subsequent declines in athletic performance. Curcumin has anti-inflammatory and antioxidant properties. Our study showed that consuming CurcuWIN—a highly bioavailable form of curcumin—prior to exercise can improve training quality and help muscles recover faster.”
Abhijit Bhattacharya, president of OmniActive, said in the release: “OmniActive has made significant investments with a strong commitment to bring scientific validity to curcumin for sports nutrition applications… This new publication is in line with OmniActive’s scientific approach in building deeper insights into CurcuWIN’s potential benefits in sports nutrition. While there are clear positives from the study, even the limitations give our scientists and researchers additional insights on how to make our products serve our consumers better.”